Chemistry, pharmacology, and metabolism of emerging drugs of abuse

Therapeutic Drug Monitoring

Volumn 32, Issue 5, 2010, Pages 544-549

  Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

designer drugs; drugs of abuse; herbal drugs; metabolism; pharmacology

Indexed keywords

AMPHETAMINE DERIVATIVE; CYTOCHROME P450; DESIGNER DRUG; HERBACEOUS AGENT; ILLICIT DRUG; KRATOM; PHENCYCLIDINE DERIVATIVE; PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

DRUG ABUSE; DRUG EFFECT; DRUG METABOLISM; HUMAN; LIVER CLEARANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICOKINETICS; TOXICOLOGY;

AMPHETAMINES; ANIMALS; CANNABINOIDS; DESIGNER DRUGS; DRUGS, CHINESE HERBAL; FORENSIC TOXICOLOGY; HUMANS; MITRAGYNA; PHENCYCLIDINE; PHENETHYLAMINES; PIPERAZINES; SECOLOGANIN TRYPTAMINE ALKALOIDS; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 77957277136     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181eea318     Document Type: Review

References (94)

1. Maurer HH, Kraemer T, Springer D, et al. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types, a synopsis. Ther Drug Monit. 2004;26:127-131.
2. de la Torre R, Farre M, Roset PN, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004; 26:137-144.
3. Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives. Ther Drug Monit. 2002;24:277-289.
4. Meyer MR, Peters FT, Maurer HH. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxymethamphetamine and its enantiomers. Drug Metab Dispos. 2008;36: 2345-2354.
5. Meyer MR, Peters FT, Maurer HH. Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4- methylenedioxy- amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. Toxicol Lett. 2009;190:54-60.
6. Meyer MR, Peters FT, Maurer HH. Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of Nmethyl- benzodioxolyl-butanamine (MBDB, Eden) enantiomers. Biochem Pharmacol. 2009;77:1725-1734.
7. Meyer MR, Peters FT, Maurer HH. The role of human hepatic cytochrome P450 isozymes in the metabolism of racemic 3,4-methylenedioxyethylamphetamine and its single enantiomers. Drug Metab Dispos. 2009;37: 1152-1156.
8. Meyer MR, Maurer HH. Enantioselectivity in the methylation of the catecholic phase-I metabolites of methylenedioxy designer drugs and their capability to inhibit COMT catalyzed dopamine 3-methylation. Chem Res Toxicol. 2009;22:1205-1211.
9. Mueller M, Yuan J, Felim A, et al. Further studies on the role of metabolites in MDMA-induced serotonergic neurotoxicity. Drug Metab Dispos. 2009;37:2079-2086.
10. Schwaninger AE, Meyer MR, Zapp J, et al. The role of human UDP-glucuronyltransferases on the formation of the methylenedioxymethamphetamine (ecstasy) phase I metabolites R- and S-3-methoxymethamphetamine 4-O-glucuronides. Drug Metabol Dispos. 2009;37: 2212-2220.
11. Shima N, Katagi M, Kamata H, et al. Urinary excretion of the main metabolites of 3,4-methylenedioxymethamphetamine (MDMA), including the sulfate and glucuronide of 4-hydroxy-3-methoxymethamphetamine (HMMA), in humans and rats. Xenobiotica. 2008;38:314-324.
12. Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci Int. 2005;153:85-91.
13. Ewald AH, Fritschi G, Bork WR, et al. Designer drugs 2,5-dimethoxy-4- bromoamphetamine (DOB) and 2,5-dimethoxy-4-bromomethamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 2006;41:487-498. (Pubitemid 43668077)
14. Ewald AH, Fritschi G, Maurer HH. Designer drug 2,4,5- trimethoxyamphetamine (TMA-2): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 2006;41:1140-1148. (Pubitemid 44454167)
15. Ewald AH, Fritschi G, Maurer HH. Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;857:170-174. (Pubitemid 47362858)
16. Ewald AH, Puetz M, Maurer HH. Designer drug 2,5-dimethoxy-4- methylamphetamine( DOM,STP): Involvementof the cytochromeP450isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;862:252-256.
17. Ewald AH, Ehlers D, Maurer HH. Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry. Anal Bioanal Chem. 2008; 390:1837-1842.
18. Theobald DS, Staack RF, Puetz M, et al. New designer drug 2,5- dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/ mass spectrometry. J Mass Spectrom. 2005;40:1157-1172.
19. Theobald DS, Fehn S, Maurer HH. New designer drug 2,5-dimethoxy-4- propylthiophenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. J Mass Spectrom. 2005;40:105-116.
20. Theobald DS, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy-beta-phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;842:76-90.
21. Theobald DS, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-beta-phenethylamine (2C-D) in rat urine using gas chromatographic-mass spectrometric techniques. J Mass Spectrom. 2006;41:1509-1519.
22. Theobald DS, Putz M, Schneider E, et al. New designer drug 4-iodo-2,5- dimethoxy-beta-phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques. J Mass Spectrom. 2006;41:872-886.
23. Theobald DS, Fritschi G, Maurer HH. Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy-beta-phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;846:374-377. (Pubitemid 46149509)
24. Kamata HT, Shima N, Zaitsu K, et al. Metabolism of the recently encountered designer drug, methylone, in humans and rats. Xenobiotica. 2006;36:709-723.
25. Zaitsu K, Katagi M, Kamata HT, et al. Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int. 2009;188:131-139.
26. Sauer C, Peters FT, Staack RF, et al. New designer drug 1-(1- phenylcyclohexyl)-3-ethoxypropylamine (PCEPA): Studies on its metabolism and toxicological detection in rat urine using gas chromatography/ mass spectrometry. J Mass Spectrom. 2006;41:1014-1029.
27. Sauer C, Peters FT, Staack RF, et al. New designer drugs N-(1- phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and N-(1-phenylcyclohexyl)- 2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 2008;43:305-316.
28. Sauer C, Peters FT, Staack RF, et al. Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatography-mass spectrometry. J Chromatogr A. 2008;1186:380-390.
29. Sauer C, Peters FT, Staack RF, et al. Metabolism and toxicological detection of the designer drug N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatography-mass spectrometry. Forensic Sci Int. 2008;181:47-51.
30. Staack RF, Maurer HH. Metabolism of designer drugs of abuse. Curr Drug Metab. 2005;6:259-274.
31. Peters FT, Meyer MR, Fritschi G, et al. Studies on the metabolism and toxicological detection of the new designer drug 4'-methyl- alphapyrrolidinobutyrophenone (MPBP) in urine using gas chromatographymass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;824:81-91.
32. Sauer C, Peters FT, Haas C, et al. New designer drug alphapyrrolidinovalerophenone (PVP): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom. 2009;44:952-964.
33. Antia U, Tingle MD, Russell BR. Metabolic interactions with piperazinebased-party pill drugs. J Pharm Pharmacol. 2009;61:877-882.
34. Nakagawa Y, Suzuki T, Tayama S, et al. Cytotoxic effects of 3,4- methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Arch Toxicol. 2009;83:69-80.
35. Austin H, Monasterio E. Acute psychosis following ingestion of-Rapture. Australas Psychiatry. 2004;12:406-408.
36. Kalant H. The pharmacology and toxicology of-ecstasy (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-928.
37. Wood DM, Dargan PI, Button J, et al. Collapse, reported seizure-and an unexpected pill. Lancet. 2007;369:1490.
38. Philipp AA, Wissenbach DK, Zoerntlein SW, et al. Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry. J Mass Spectrom. 2009;44:1249-1261.
39. Philipp AA, Wissenbach DK, Weber AA, et al. Use of liquid chromatography coupled to low and high resolution linear ion trap mass spectrometry for studying the metabolism of paynantheine, an alkaloid of the herbal drug Kratom in rat and human urine. Anal Bioanal Chem. 2010; 396:2379-2391.
40. Auwarter V, Dresen S,WeinmannW, et al.-Spice and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009; 44:832-837.
41. Lindigkeit R, Boehme A, Eiserloh I, et al. Spice: a never ending story? Forensic Sci Int. 2009;191:58-63.
42. Hiramatsu M, Kumagai Y, Unger SE, et al. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther. 1990;254:521-527.
43. Meyer MR, Maurer HH. Metabolism of designer drugs of abuse-an update. Curr Drug Metab. 2010;11:468-482.
44. Peters FT, Martinez-Ramirez JA. Analytical toxicology of emerging drugs of abuse. Ther Drug Monit. 2010;32:532-539.
45. Shulgin A. Pihkal, a Chemical Love Story, 1st ed. Berkley, CA: Transform Press; 1991.
46. Acuna-Castillo C, Villalobos C, Moya PR, et al. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors. Br J Pharmacol. 2002;136: 510-519.
47. Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35: 2505-2511.
48. Glennon RA, McKenney JD, Lyon RA, et al. 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986;29:194-199.
49. Glennon RA, Titeler M, Seggel MR, et al. N-methyl derivatives of the 5-HT2 agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. J Med Chem. 1987;30:930-932.
50. Glennon RA, Raghupathi R, Bartyzel P, et al. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J Med Chem. 1992;35:734-740.
51. Monte AP, Marona-Lewicka D, Parker MA, et al. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl) alkylamine derivatives with rigidified methoxy groups. J Med Chem. 1996;39:2953-2961.
52. Body S, Cheung TH, Bezzina G, et al. Effects of d-amphetamine and DOI (2,5-dimethoxy-4-iodoamphetamine) on timing behavior: interaction between D1 and 5-HT2A receptors. Psychopharmacology (Berl). 2006; 189:331-343.
53. Dimpfel W, Spuler M, Nichols DE. Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG). Psychopharmacology (Berl). 1989;98: 297-303.
54. Ewald AH, Maurer HH. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. Toxicol Lett. 2008;183:52-57.
55. Ho BT, Estevez V, Fritchie GE. The fate of 2,5-dimethoxy-4- methylamphetamine (STP, DOM) in monkey and rat brains. Brain Res. 1971;29:166-169.
56. Ho BT, Estevez V, Tansey LW, et al. Analogs of amphetamine. 5. Studies of excretory metabolites of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats. J Med Chem. 1971;14:158-160.
57. Johnson MP, Mathis CA, Shulgin AT, et al. [125I]-2-(2,5-dimethoxy-4- iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex. Pharmacol Biochem Behav. 1990;35:211-217.
58. Glennon RA, Titeler M, Lyon RA. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse. Pharmacol Biochem Behav. 1988;30:597-601.
59. Villalobos CA, Bull P, Saez P, et al. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) and structurally related phenylethylamines are potent 5-HT2A receptor antagonists in Xenopus laevis oocytes. Br J Pharmacol. 2004;141:1167-1174.
60. Fantegrossi WE, Harrington AW, Eckler JR, et al. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology (Berl ). 2005;181:496-503.
61. Lobos M, Borges Y, Gonzalez E, et al. The action of the psychoactive drug 2C-B on isolated rat thoracic aorta. Gen Pharmacol. 1992;23: 1139-1142.
62. Saez P, Borges Y, Gonzalez E, et al. Alpha-adrenergic and 5-HT2- serotonergic effects of some beta-phenylethylamines on isolated rat thoracic aorta. Gen Pharmacol. 1994;25:211-216.
63. Braun U, Shulgin AT, Braun G, et al. Synthesis and body distribution of several iodine-131 labeled centrally acting drugs. J Med Chem. 1977; 20:1543-1546.
64. Glennon RA, Kier LB, Shulgin AT. Molecular connectivity analysis of hallucinogenic mescaline analogs. J Pharm Sci. 1979;68:906-907.
65. Gupta SP, Bindal MC, Singh P. Quantitative structure-activity studies on hallucinogenic mescaline analogs using modified first order valence connectivity. Arzneim-Forsch. 1982;32:1223-1225.
66. Kier LB, Glennon RA. Progress with several models for the study of the SAR of hallucinogenic agents. NIDA Res Monogr. 1978;22: 159-185.
67. Beuerle G, Kovar KA, Schulze-Alexandru M. Three-dimensional quantitative structure-activity relationships of hallucinogenic phenylalkanamine and tryptamine derivatives. Studies using comparative molecular field analysis (CoMFA). Quant Struct-Act Relat. 1997;16: 447-458.
68. Bienfait B. Applications of high-resolution self-organizing maps to retrosynthetic and QSAR analysis. J Chem Inf Comput Sci. 1994;34: 890-898.
69. Clare BW. The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens. J Med Chem. 1998;41:3845-3856.
70. Klopman G, Macina OT. Use of the Computer Automated Structure Evaluation program in determining quantitative structure-activity relationships within hallucinogenic phenylalkylamines. J Theor Biol. 1985;113:637-648.
71. Mracec M, Mracec M, Kurunczi L, et al. QSAR study with steric (MTD), electronic and hydrophobicity parameters on psychotomimetic phenylalkylamines. THEOCHEM. 1996;367:139-149.
72. de Boer D, dos Reys LA, Pylon N, et al. Preliminary results on the urinary excretion of 2C-B (4-bromo-2,5-dimethoxyphenethylamine) and its metabolites in humans. Br J Pharmacol. 1999;127:41P.
73. Kanamori T, Inoue H, Iwata Y, et al. In vivo metabolism of 4-bromo-2,5- dimethoxyphenethylamine (2C-B) in the rat: identification of urinary metabolites. J Anal Toxicol. 2002;26:61-66.
74. Lin LC, Liu JT, Chou SH, et al. Identification of 2,5-dimethoxy-4- ethylthiophenethylamine and its metabolites in the urine of rats by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;798:241-247.
75. Kanamori T, Tsujikawa K, Ohmae Y, et al. Excretory profile of 4-bromo-2,5-dimethoxy-phenethylamine (2C-B) in rat. J Health Sci. 2003;49:166-169.
76. Carmo H, Hengstler JG, de Boer D, et al. Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:198-205.
77. Kanamori T, Tsujikawa K, Ohmae Y, et al. A study of the metabolism of methamphetamine and 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in isolated rat hepatocytes. Forensic Sci Int. 2005;148:131-137.
78. Carmo H, Boer D, Remiao F, et al. Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 811:143-152.
79. Carmo H, Hengstler JG, de Boer D, et al. Metabolic pathways of 4-bromo- 2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology. 2005;206: 75-89.
80. Theobald DS, Maurer HH. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine- derived designer drugs (2C-series). Biochem Pharmacol. 2007;73: 287-297.
81. Meyer MR, Wilhelm J, Peters FT, et al. Beta-keto designer drugs: Studies on the metabolism of mephedrone and toxicological detection of mephedrone, butylone and methylone in urine using gas chromatography- mass spectrometry. Anal Bioanal Chem. 2010;397:1225-1233.
82. Roesner P, Junge T, Fritschi G, et al. Neue synthetische Drogen: Piperazin-, Procyclidin- und alpha-Aminopropiophenonderivate. Toxichem Krimtech. 1999;66:81-90.
83. Maddox VH, Godefroi EF, Parcell RF. Synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem. 1965;8:230-235.
84. Rang HP, Dale MM, Ritter JM, eds. Pharmacology, 4th ed. London: Churchill Livingston; 1999.
85. Takeda H, Gazzara RA, Howard SG. Phenylcyclohexylamine: effect of a metabolite of phencyclidine on the efflux of dopamine in the rat. Neuropharmacology. 1986;25:1341-1345.
86. Sauer C, Peters FT, Schwaninger AE, et al. Identification of cytochrome P450 enzymes involved in the metabolism of the designer drugs N- (1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA) and N-(1-phenylcyclohexyl)- 3-methoxypropanamine (PCMPA). Chem Res Toxicol. 2008; 21:1949-1955.
87. Sauer C, Peters FT, Schwaninger AE, et al. Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenylcyclohexyl)-2-ethoxyethanamine and N-(1- phenylcyclohexyl)-2- methoxyethanamine. Biochem Pharmacol. 2009;77: 444-450.
88. Shellard EJ. The alkaloids of Mitragyna with special reference to those of Mitragyna speciosa, Korth. Bull Narc. 1974;26:41-55.
89. Ponglux D, Wongseripipatana S, Takayama H, et al. A new indole alkaloid, 7 alpha-hydroxy-7H-mitragynine, from Mitragyna speciosa in Thailand. Planta Med. 1994;60:580-581.
90. Matsumoto K, Horie S, Ishikawa H, et al. Antinociceptive effect of 7-hydroxymitragynine in mice: discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2004;74:2143-2155.
91. Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27: 21-27.
92. Jansen KL, Prast CJ. Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol. 1988;23:115-119.
93. Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo). 2004;52:916-928.
94. Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila). 2008;46:146-152.